Journal article

Thiazolidinediones and type 2 diabetes: new drugs for an old disease

TM O'Moore-Sullivan, JB Prins

MEDICAL JOURNAL OF AUSTRALIA | AUSTRALASIAN MED PUBL CO LTD | Published : 2002

Abstract

Thiazolidinediones are a new class of drugs for the treatment of type 2 diabetes, and act by improving insulin sensitivity in adipose tissue, liver and skeletal muscle. Rosiglitazone and pioglitazone are registered for use in monotherapy, and in combination with sulfonylureas and metformin. Pioglitazone is also licensed for use in combination with insulin. There is level II evidence that in patients with inadequate glycaemic control both drugs reduce the level of HbA1c and fasting plasma glucose (FPG) when used as monotherapy and in combination with sulfonylurea or metformin or insulin; and both drugs increase levels of HDL and LDL and lower free fatty acid levels, but only pioglitazone sign..

View full abstract

University of Melbourne Researchers